| 1. |
Implications for antivirals in HBV infection |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Development of respiratory syncytial virus vaccines |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Genotype-based dosing strategy for azathioprine valid in RA, SLE |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Medication review reduces costs in elderly patients |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Rimonabant reduces risk factors for cardiovascular disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 7-9
RM Poole,
Preview
|
|
摘要:
Treatment with rimonabant [Acomplia], a selective CB1receptor blocker, is effective in reducing bodyweight in overweight/obese patients with untreated dyslipidaemia, and also results in prolonged cessation of smoking without significant weight gain, according to two phase III studies presented at the 53rd Annual Scientific Session of the American College of Cardiology [New Orleans, US; March 2004].1In the first study, prolonged abstinence from smoking was achieved in significantly more rimonabant 20mg, compared with placebo, recipients; no significant increase in bodyweight was observed among these patients. The second study showed that rimonabant was effective in reducing bodyweight and waist circumference, and improving serum lipid profiles, in overweight or obese patients with dyslipidaemia. Furthermore, a significant reduction from baseline in the number of patients with metabolic syndrome was observed with rimonabant 20mg. These studies suggest that, subject to approval, rimonabant will be the first drug to target multiple risk factors for cardiovascular disease.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
CCI 779 active in refractory metastatic renal cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
The nonsteroidal anti-inflammatory agent bromfenac*can successfully treat ocular inflammation, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Omalizumab attenuates early responses in allergic rhinitis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Inhaled insulin effective, well tolerated in type 2 diabetes |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
ALLIANCE: atorvastatin advantageous in coronary heart disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1429,
2004,
Page 13-14
RM Poole,
Preview
|
|
摘要:
Aggressive lipid-lowering with atorvastatin [Lipitor] provides greater cardiovascular benefits than usual medical care in patients with coronary heart disease (CHD), according to results from a study presented at the 2004 Annual Scientific Session of the American College of Cardiology [New Orleans, US; March 2004]. The ALLIANCE study, which involved > 2400 patients in the managed care setting, showed that treatment with atorvastatin produced significant reductions in the combined incidence of major adverse cardiac events, and in the occurrence of nonfatal myocardial infarction (MI), compared with usual care.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
